Business Wire

Origins and The Estée Lauder Companies Announce Sustainable Packaging Partnership With SABIC and Albéa

14.10.2020 16:06:00 EEST | Business Wire | Press release

Share

Origins, a prestige global skincare brand that delivers high-performance formulas powered by nature and proven by science, and its parent company, The Estée Lauder Companies (ELC), today announced a partnership with global chemical industry leader SABIC and strategic beauty packaging manufacturer Albéa to bring an advanced recycled tube package to market in 2021.

Origins will be the first prestige beauty brand to leverage SABIC’s innovative, advanced recycling technology to produce a tube pack format made from previously difficult to recycle, post-consumer mixed plastics material.

Launching with Origins global best-selling mask, Clear Improvement™ Active Charcoal Mask will be packaged in a tube composed of a circular polymer resin made using SABIC’s revolutionary, certified circular polyethylene and polypropylene advanced recycling technology. As a pioneer in the development of sustainable packaging for beauty brands, Albéa will leverage its expertise in the use of recycled resins to deliver a high-performing tube experience.

Traditional recycling streams for plastics are limited, and plastics can only be recycled a finite amount of times. Advanced recycling returns hard-to-recycle plastics, otherwise destined for incineration or landfill, back to their basic building blocks. Once the plastic has been broken down to its molecular state, it is then used to create high-performance plastics akin to a virgin material. SABIC’s ground-breaking, certified circular polymer, part of its TRUCIRCLE™ portfolio of circular solutions, uses this technology which is capable of continually converting plastics back to the original polymer. Through the use of this innovative recycling technology, Origins, ELC, SABIC and Albéa are helping to drive innovation across the value chain toward the goal of a circular plastic economy.

This strategic partnership aligns with ELC’s sustainable packaging goals, which includes increasing the amount of post-consumer recycled (PCR) material in its packaging by up to 50% by 2025, and will further Origins efforts to ensure that at least 80% of the brand’s packaging by weight is recyclable, refillable, reusable, recycled or recoverable by 2023.

SABIC's certified polymers are based on a mass balance approach. To secure the chain of custody, the value chain parties require an ISCC PLUS certification. This widely recognized international sustainability certification scheme verifies that the mass balance accounting follows predefined and transparent rules. In addition, it provides traceability along the supply chain, from the feedstock to the final product.

“Respect for the well-being of your skin and our planet is ingrained into our brand’s DNA. It guides our actions and is reflected in our Origins offerings which is why we’re excited to partner with SABIC and Albéa to provide our consumers with a safe, high-quality and responsible packaging solution that helps reduce our impact on the environment,” says Francesca Damato, Origins Vice President Global Marketing and Product Development. “Together, we have an exciting opportunity to define how the prestige beauty industry can create sustainable, attractive packaging solutions that please both consumer and the planet. This is a significant first step in the transition towards a circular economy, helping to close the loop on plastic waste.”

“At The Estée Lauder Companies, we approach sustainable design options for our prestige and luxury packaging with a spirit of collaboration. To further our focus on reducing the potential environmental impacts of a package across its lifecycle, we are proud to partner with SABIC and Albéa on Origins industry-first sustainable packaging innovation,” said Sushil Iyer, Vice President, Global Packaging, The Estée Lauder Companies. “Exploring the uses of advanced recycled PCR has incredible potential to help drive the achievement of our sustainable packaging goals, and we are excited to bring this product to market.”

Mark Vester, Circular Economy Leader at SABIC, said “The new Origins packaging is the result of true collaboration and innovation, and another step closer to closing the loop on used plastics. We are committed to collaborating with partners across the value chain to work towards a more sustainable, circular future.”

“Albéa has been at the forefront of sustainable development in packaging for many years and was the first beauty packaging company to commit to making their solutions 100% circular by 2025. This breakthrough with Origins, The Estée Lauder Companies and SABIC is an industry first – paving the way for the use of advanced recycled, post-consumer waste into prestige beauty packaging thanks to an innovative source of high-quality resins,” says Stéphane Barlet, VP of Sales, Albéa Americas. “This co-development also highlights the importance of partnership and audacity across the value-chain, which is crucial to accelerate the transition to recyclable and reusable packaging."

About Origins

Prestige global skincare brand, Origins combines high-quality plant, earth and sea-based ingredients with non-toxic-to-skin alternatives and advanced science to create safe, high-performance products that deliver transformative results. Since inception in 1990, Origins has been committed to respecting the well-being of your skin and our planet – from traveling the world to discover nature’s potent ingredients to endeavoring to make choices that help reduce our impact on the planet. The brand formulates without: parabens, phthalates, propylene glycol, formaldehyde, sodium lauryl sulfate (SLS), mineral oil, petrolatum, paraffin, diathanolamine (DEA), polyethylene beads and animal ingredients (except cruelty free honey & beeswax). Origins is available in 30 countries. For more information, visit www.origins.com; never stop discovering™ and follow @Origins.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

About SABIC

SABIC is a global leader in diversified chemicals and the company manufacture on a global scale in the Americas, Europe, Middle East and Asia Pacific, making distinctly different kinds of products: chemicals, commodity and high performance plastics, agri-nutrients and metals.

At SABIC, we are working to drive the change needed to close the loop on used plastic. This includes SABIC’s TRUCIRCLE™ portfolio and services which showcases our circular innovations, including our certified circular products which are produced using a feedstock derived from previously difficult to recycle used plastic household packaging. We are collaborating with retailers, recyclers and manufacturers to close the loop and to accelerate the changes we need to make to become a circular global society.

SABIC has more than 33,000 employees worldwide and operates in around 50 countries. Fostering innovation and a spirit of ingenuity, we have 12,540 global patent filings, and have significant research resources with innovation hubs in five key geographies – USA, Europe, Middle East, South Asia and North Asia.

Visit our website for more information: www.sabic.com.

About Albéa

We invent and make responsible packaging – tubes, lipsticks, mascaras, fragrance caps, skincare jars and turnkey solutions – for the beauty, personal care and health markets. Yet we believe there can be no responsible packaging without a responsible company. That’s why we uphold the reputation of our dynamic and prestigious customers; we act for the environment; we support our communities; we invest in technical expertise and world-class equipment for our 32 modern facilities worldwide; and we care for our 12,000 talented people. At Albéa, we protect Beauty. www.albea-group.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Origins: Alicja Wojczyk, awojczyk@estee.com
The Estée Lauder Companies: Kyle Landman klandman@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye